Last reviewed · How we verify
carboplatin/cisplatin-etoposide
carboplatin/cisplatin-etoposide is a platinum-based chemotherapeutic agents Small molecule drug developed by Shanghai Henlius Biotech. It is currently in Phase 3 development for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death.
Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death. Used for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | carboplatin/cisplatin-etoposide |
|---|---|
| Sponsor | Shanghai Henlius Biotech |
| Drug class | platinum-based chemotherapeutic agents |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin and cisplatin-etoposide are platinum-based chemotherapeutic agents that form platinum-DNA adducts, which trigger DNA damage response and apoptosis in rapidly dividing cancer cells. Etoposide, a topoisomerase inhibitor, further enhances DNA damage by preventing DNA repair and promoting cell death.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
- Ovarian cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin/cisplatin-etoposide CI brief — competitive landscape report
- carboplatin/cisplatin-etoposide updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI
Frequently asked questions about carboplatin/cisplatin-etoposide
What is carboplatin/cisplatin-etoposide?
How does carboplatin/cisplatin-etoposide work?
What is carboplatin/cisplatin-etoposide used for?
Who makes carboplatin/cisplatin-etoposide?
What drug class is carboplatin/cisplatin-etoposide in?
What development phase is carboplatin/cisplatin-etoposide in?
What are the side effects of carboplatin/cisplatin-etoposide?
What does carboplatin/cisplatin-etoposide target?
Related
- Drug class: All platinum-based chemotherapeutic agents drugs
- Target: All drugs targeting DNA
- Manufacturer: Shanghai Henlius Biotech — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Ovarian cancer
- Compare: carboplatin/cisplatin-etoposide vs similar drugs
- Pricing: carboplatin/cisplatin-etoposide cost, discount & access